X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs DR. REDDYS LAB - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA DR. REDDYS LAB CIPLA/
DR. REDDYS LAB
 
P/E (TTM) x 34.5 25.8 133.7% View Chart
P/BV x 3.0 3.2 94.5% View Chart
Dividend Yield % 0.6 0.8 68.1%  

Financials

 CIPLA   DR. REDDYS LAB
EQUITY SHARE DATA
    CIPLA
Mar-18
DR. REDDYS LAB
Mar-18
CIPLA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs6632,788 23.8%   
Low Rs4791,902 25.2%   
Sales per share (Unadj.) Rs189.0860.8 22.0%  
Earnings per share (Unadj.) Rs17.657.1 30.8%  
Cash flow per share (Unadj.) Rs34.0122.0 27.9%  
Dividends per share (Unadj.) Rs3.0020.00 15.0%  
Dividend yield (eoy) %0.50.9 61.6%  
Book value per share (Unadj.) Rs176.7757.7 23.3%  
Shares outstanding (eoy) m805.12165.91 485.3%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.02.7 110.9%   
Avg P/E ratio x32.541.1 79.0%  
P/CF ratio (eoy) x16.819.2 87.3%  
Price / Book Value ratio x3.23.1 104.4%  
Dividend payout %17.135.0 48.7%   
Avg Mkt Cap Rs m459,724389,034 118.2%   
No. of employees `00023.623.5 100.4%   
Total wages/salary Rs m26,90132,149 83.7%   
Avg. sales/employee Rs Th6,446.16,070.8 106.2%   
Avg. wages/employee Rs Th1,139.41,366.6 83.4%   
Avg. net profit/employee Rs Th600.0402.5 149.1%   
INCOME DATA
Net Sales Rs m152,193142,810 106.6%  
Other income Rs m3,5771,552 230.4%   
Total revenues Rs m155,769144,362 107.9%   
Gross profit Rs m28,26423,512 120.2%  
Depreciation Rs m13,22810,772 122.8%   
Interest Rs m1,142788 145.0%   
Profit before tax Rs m17,47013,504 129.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-28344 -8.1%   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,5014,380 57.1%   
Profit after tax Rs m14,1669,468 149.6%  
Gross profit margin %18.616.5 112.8%  
Effective tax rate %14.332.4 44.1%   
Net profit margin %9.36.6 140.4%  
BALANCE SHEET DATA
Current assets Rs m108,141104,984 103.0%   
Current liabilities Rs m38,32268,938 55.6%   
Net working cap to sales %45.925.2 181.8%  
Current ratio x2.81.5 185.3%  
Inventory Days Days9774 130.5%  
Debtors Days Days74104 71.8%  
Net fixed assets Rs m109,411104,385 104.8%   
Share capital Rs m1,610830 194.0%   
"Free" reserves Rs m140,682124,886 112.6%   
Net worth Rs m142,292125,716 113.2%   
Long term debt Rs m36,62125,089 146.0%   
Total assets Rs m228,606225,443 101.4%  
Interest coverage x16.318.1 89.8%   
Debt to equity ratio x0.30.2 129.0%  
Sales to assets ratio x0.70.6 105.1%   
Return on assets %6.74.5 147.2%  
Return on equity %10.07.5 132.2%  
Return on capital %10.09.7 102.6%  
Exports to sales %32.80-   
Imports to sales %00-   
Exports (fob) Rs m49,883NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,69172,623 71.2%   
Fx outflow Rs m21,03318,916 111.2%   
Net fx Rs m30,65853,707 57.1%   
CASH FLOW
From Operations Rs m14,62818,030 81.1%  
From Investments Rs m-8,540-14,883 57.4%  
From Financial Activity Rs m-3,855-4,440 86.8%  
Net Cashflow Rs m2,431-1,236 -196.7%  

Share Holding

Indian Promoters % 16.0 25.5 62.7%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 5.4 225.9%  
FIIs % 23.7 35.3 67.1%  
ADR/GDR % 1.1 18.5 5.9%  
Free float % 26.2 15.3 171.2%  
Shareholders   161,166 75,885 212.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   UNICHEM LAB  AUROBINDO PHARMA  PFIZER  GLENMARK PHARMA  VENUS REMEDIES  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 345 Points Lower; Auto and Telecom Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Nov 12, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS